News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Sanofi Loses Three Top Execs in Reshuffle

May 23, 2016

Article

May 23, 2016.

Three of Sanofi's (Paris, France) top executives are leaving the company as its "2020 strategic roadmap" gets under way.

Pascale Witz, executive vice president of diabetes and cardiovascular, Carsten Hellmann, executive vice president of Merial, Sanofi’s animal health division, and Suresh Kumar, executive vice president of external affairs, have announced their intention to leave the company.

Hellmann has accepted a position as president and CEO of ALK (Horsholm, Denmark).

Related Content

AI in Pharma: Where, When, and How Executives are Considering it

Gaugarin Oliver

November 19th 2024

Article

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problems

Mike Hollan

November 15th 2024

Article

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Leap Forward: Practical Gains for Pharma AI Use

Bianca Anghelina;Helen Merianos;Ruth Beadle

November 14th 2024

Article

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.